Tukysa
Pfizer Reports 27 Percent Oncology Growth in Q4, Touts Progress in ADC and Breast Cancer Trials
Premium
The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period in 2023.
Pfizer's oncology revenues jumped 30 percent in the third quarter, with growth from several precision oncology drugs.
Tukysa-Kadcyla Combo Shows Efficacy in HER2-Positive Breast Cancer Patients With Brain Metastases
Premium
Researchers at SABCS said data from HER2CLIMB-02 could influence imaging and treatment strategies for patients whose breast cancer has spread to the brain.
European Commission Approves Pfizer Acquisition of Seagen
Once the deal closes later this year or early next year, Pfizer will gain the HER2-targeted agent Tukysa and about a dozen other Seagen oncology assets.